Analyst Chris Schott from J.P. Morgan maintained a Buy rating on Regeneron (REGN – Research Report) and keeping the price target at $1,100.00. Chris Schott has given his Buy rating due to a ...

San Francisco, California--(Newsfile Corp. - January 30, 2025) - Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) faces a securities fraud class action after shares of the company plunged $84.59 on ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other S&P 500 stocks. 2024 was a memorable year for the broad market index ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Regeneron and Illumina have joined a major investment in health data specialist Truveta that will support the creation of a major new genome project. The two companies, along with 17 US health ...

Regeneron is the second pharma group to sign up for access to data from a remote study run by health technology firm Koneksa that is exploring the use of digital biomarkers to track patients with ...

Duke and North Carolina's seasons are going in opposite directions. Duke has won 14 straight going back to Nov. 29, are undefeated in the ACC (10-0), and ranked No. 2 in the AP Top 25 Poll.